Primary Biliary Cholangitis Insights

UK Approves Gilead's Livdelzi for Adult Liver Disease Treatment

Gilead's Livdelzi has been approved by the MHRA to treat primary biliary cholangitis in adults, offering a new treatment option. This approval marks a significant development for patients managing this condition.

New Medication Seladelpar Approved for UK Patients with Liver Illness

Seladelpar, a new medication, has been approved in the UK to treat adult patients with primary biliary cholangitis, a liver illness. This approval provides another treatment option for managing the condition and its symptoms.

FDA Warns of Liver Injury Risk with Obeticholic Acid Use

The FDA has issued a warning about serious liver injury associated with obeticholic acid, a medication used to treat primary biliary cholangitis. Patients should be closely monitored for signs of liver damage while taking this drug.

Recent studies have highlighted a potential link between SARS-CoV-2 infection and the manifestation of autoimmune liver diseases such as primary biliary cholangitis (PBC). According to Lee et al. (2025), there have been instances where PBC emerged following COVID-19, suggesting a possible trigger relationship. This observation is supported by another study in Cho et al. (2025), which advises considering PBC among other forms of cholangitis post-COVID-19 infection.

Furthermore, the treatment landscape for PBC is evolving, as noted in Komori & Kugiyama (2025). Patients who do not respond to traditional therapies or cannot tolerate them are now being identified, paving the way for new treatment approaches. These findings underscore the importance of monitoring liver health following COVID-19 and the need for ongoing research into effective treatments for PBC.